Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study.
This report describes the preparation of an immunotoxin-combination, consisting of an anti-CD3 and anti-CD7 monoclonal antibody (MoAb) both conjugated to the A-chain of plant toxin ricin, for the experimental treatment of graft-versus-host disease. MoAbs and toxin were conjugated by conventional biochemical and chromatographic techniques. Raw materials, intermediate and final products were evaluated in accordance with the relevant 'points to consider' of the FDA. Yields, purity and sterility of the two final products were all satisfactory. Preservation of MoAb-affinity and toxin-activity were confirmed in biological assays. The LD50, 25-45 mg immunotoxin-combination/kg mouse, equalled that of similar immunotoxins already in clinical use. Because in vitro cross-reactivity screening revealed an unexpected binding of the CD3-MoAb to the esophagus epithelium, human doses of immunotoxin-combination were administered to two cynomolgus monkeys. Clinically relevant serum concentrations were obtained without irreversible toxicities occurring. The T(1/2) varied between approximately 6 and 9 h and the C(max) ranged from 1.8 to 3.9 microg/ml. The main side effect was a transient rise of serum creatine kinase. Importantly, neither damage nor binding of the CD3-immunotoxin to the monkey esophagus epithelium could be demonstrated. It was concluded that sufficient material of proper quality and with an acceptable toxicity profile was produced, warranting the evaluation in a clinical pilot-study.
van Oosterhout
Y V
YV
Department of Hematology, University Medical Center St Radboud, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands. y.vanoosterhout@chl.azn.nl
van Emst
J L
JL
Bakker
H H
HH
Preijers
F W
FW
Schattenberg
A V
AV
Ruiter
D J
DJ
Evers
S
S
Koopman
J P
JP
de Witte
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D019540:Area Under Curve; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D006086:Graft vs Host Disease / Q000276:immunology*; D006207:Half-Life; D006801:Humans; D000922:Immunotoxins / Q000493:pharmacokinetics* / Q000633:toxicity; D007928:Lethal Dose 50; D008252:Macaca fascicularis; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D008807:Mice, Inbred BALB C; D011786:Quality Control; D012276:Ricin / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D012276:Ricin